Stock Analysis
Immunome, Inc. (IMNM) Stock Analysis
Immunome, Inc. (IMNM) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Immunome, Inc. (IMNM) currently has an AIQ Score of 48/100, indicating a bearish setup. Quality is the strongest factor at 52/100. Momentum is the weakest current factor at 45/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
IMNM at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $18.77 |
| AIQ Score | 48/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Sell |
| Market Cap | $2.13B |
| P/E Ratio (TTM) | -7.08 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.76 |
| Revenue (Q3 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.47 |
| Volume | 951.08K |
| 52-week range | $16.11-$30.06 |
| RSI 14 | 46.9 |
| 50-Day SMA | $20.65 |
| 200-Day SMA | $22.21 |
| Analyst Price Target | $27.00 |
| Next Earnings | Mar 2, 2027 |
IMNMImmunome, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum45
- Value—
- Quality52
- Risk resilience47
- Sentiment—
IMNM Stock Analysis Summary
Immunome, Inc. (IMNM) currently has an AIQ Score of 48/100, indicating a bearish setup. Quality is the strongest factor at 52/100. Momentum is the weakest current factor at 45/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, IMNM has AIQ Score of 48/100 with Quality base of 52/100 and fading Momentum at 45/100. Wait for component alignment before adding exposure.
Healthcare · 0.37% stock move · IMNM classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is IMNM Bullish or Bearish Right Now?
IMNM currently has a bearish overall setup. Quality is the strongest factor at 52/100, while Momentum is weakest at 45/100. The current evidence suggests a bearish setup.
- - Analyst target implies +43.85% upside from the latest quote.
- - Momentum is weak at 45/100.
- - Risk Resilience is weak at 47/100.
- - Price is -15.50% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (22 vs 15).
Current Consensus
IMNM's Technical Analysis Consensus is currently Sell, with 15 buy, 9 neutral, and 22 sell votes. IMNM's 14-day RSI is 46.9, which places the stock in a neutral momentum range. IMNM's beta is 1.47, indicating greater market sensitivity than the broad market.
What Changed in IMNM?
The largest recent change in IMNM is Quality moving down by 8.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the IMNM Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
IMNM Decision Framework
Public evidence layers, setup checks, and risk context for Immunome, Inc..
Immunome, Inc. (IMNM) Stock Analysis
Immunome, Inc. has an AIQ Score of 48/100 in a Bearish regime. Quality is strongest at 52/100. Beta is 1.47, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | IMNM is in a Bearish AIQ regime with score 48/100. |
| Signal Conflict | The primary conflict is that quality leads at 52/100 while momentum lags at 45/100. |
| Factor Evidence | Momentum 45/100 · Quality 52/100 · Risk 47/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 52/100.
Momentum is 45/100 and RSI (14) is 46.9.
IMNM is in a Bearish regime at 48/100.
Risk factor is 47/100 with beta 1.47 and annual volatility 60.72%.
Current conflict: quality leads at 52/100 while momentum lags at 45/100.
IMNM Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
IMNM Fundamentals
IMNM valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
IMNM Technical Analysis
IMNM technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
IMNM Stock Catalysts
Track IMNM earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
IMNM Dividend Analysis
IMNM dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
IMNM Financial Data
IMNM revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
IMNM Risk Analysis
IMNM volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
IMNM Stock News
IMNM stock news, market tone, recent headlines, and catalyst context.
IMNM vs Biotechnology Peers
Current peer cohort: IMNM · IMVT · INBX · INSM · INVA. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| IMNM Current stock | 48/100 | — | 45/100 | 47/100 | 0.45 | 60.72% | Current |
| IMVT Immunovant, Inc. | 52/100 | — | 61/100 | 52/100 | 0.9 | 58.62% | IMNM vs IMVT |
| INBX Inhibrx Biosciences Inc. | 40/100 | — | 50/100 | 40/100 | 0.49 | 82.28% | IMNM vs INBX |
| INSM Insmed Incorporated | 57/100 | 55/100 | 61/100 | 49/100 | -0.48 | 63.12% | IMNM vs INSM |
| INVA Innoviva, Inc. | 67/100 | 92/100 | 43/100 | 74/100 | -0.64 | 25.21% | IMNM vs INVA |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for IMNM: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching IMNM
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for IMNM
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
IMNM Stock FAQ
What is IMNM stock price today?
Immunome, Inc.'s current stock price is $18.77. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is IMNM bullish or bearish right now?
IMNM's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is IMNM's market cap?
IMNM's market cap is $2.13B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is IMNM's current P/E ratio?
IMNM's current P/E ratio is -7.08 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is IMNM's RSI?
IMNM's 14-day RSI is 46.9 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is IMNM above its 50-day and 200-day moving averages?
IMNM is -9.11% from its 50-day SMA and -15.50% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is IMNM's next earnings date?
IMNM's next earnings date is currently listed as Mar 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does IMNM pay a dividend?
IMNM's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.